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Longitudinal follow-up of CA125 in peritoneal effluent. Mesothelial
changes occur during peritoneal dialysis. CA125 provides a way to study
the mesothelial cells in the in vivo situation. In the present study
longitudinal changes of CA125 were analyzed. In addition, the appearance
of CA125 in peritoneal effluent and day-to-day variability were studied.
CAl 25 was measured in the effluent of five stable CAPD patients during
four hour dwells with 1.36% glucose, with 3.86% glucose and with 7.5%
icodextrin. In addition, CA125 was determined on six consecutive days in
four hour effluents of three patients and appearance rates (AR) were
calculated. Longitudinal follow-up was performed in 31 patients in whom
three to seven yearly observations had been made. Linear appearance of
CA125 was present in all dwells. No difference was found between the
appearance rates of CA125 with 3.86% glucose, compared to either 1.36%
glucose or icodextrin. Mean day-to-day coefficient of variation was 6.4%
for CA125 AR, but a wide variation existed in stable CA125 values among
patients (mean 22.1, range 2 to 48 U/mI). A negative trend with duration
of CAPD was present in the longitudinal study. A mean decrease of 2.2%
per year could be calculated, but substantial interindividual differences
existed. Sudden decreases of CA125 AR were found in five patients.
Possible causes were found in all of them and included a severe or
recurrent peritonitis, and temporary cessation of peritoneal dialysis. In
one patient a sudden decrease preceded the manifestation of peritoneal
sclerosis. It can be concluded that CA125 can be used for the in vivo
follow-up of the mesothelium in peritoneal dialysis patients. The appear-
ance of CA125 in effluent is linear in time and not influenced by the initial
lysis of mesothelial cells. A gradual loss of mesothelial cells is likely to
occur, although interindividual variability is substantial. An acceleration of
the process may be caused by severe peritonitis and perhaps by temporary
cessation of peritoneal dialysis. A sudden decrease in CAl 25 may be an
alarming sign for the development or manifestation of peritoneal sclerosis.
Changes in the mesothelial cells lining the peritoneal cavity
have been described in peritoneal dialysis patients. These data
were mainly derived from studies on peritoneal biopsies taken at
catheter removal or reinsertion [1—4], or from animal studies
investigating either peritoneal tissue specimens [3, 5] or mesothc-
hal cells obtained by an imprint technique [6]. The reported
changes in the mesothelium can be summarized as glucose-
induced degenerative changes in isolated cells [6], activation in
stable patients, loss of mesothelial cells in some patients treated
with CAPD for a long period of time, and temporary loss of
mesothelial cells during uncomplicated peritonitis [1—4]. In addi-
tion, in peritoneal sclerosis a lack of remesothelialization has been
described [7]. A pivotal role of the mesothelial cells in peritoneal
host defense has been made likely based on in vitro studies on
human peritoneal mesothehial cells [reviewed in 8], and in an in
vivo study of our group showing a relation between mesothehial
cell count in peritoneal effluent and peritonitis incidence [9]. A
loss of, or dysfunctional mesothelium may therefore be a potential
risk factor in the elimination of micro-organisms and regulation of
the inflammatory reaction.
The in vivo study of the mesothelium has become possible by
the discovery of cancer antigen (CA) 125 as a marker of mesothe-
hal cell mass or cell turnover in stable CAPD patients [10, 11].
Originally used as a tumor-marker for non-mucous ovarian car-
cinomas [12], further studies using the 0C125 antibody against
CA125 [13] reported that this 220 kDa glycoprotein was not only
expressed by ovarian neoplasms, but was present also in mesothe-
hal cells of both pleural and peritoneal tissue. Subsequently, it was
demonstrated in mesothelial cells in peritoneal effluent of perito-
neal dialysis patients [10], and proved to be expressed at a
constant rate by confluent mesothelial cell monolayers in vitro,
without any effect of stimulation with interleukin-1, TNFa, or
interferon-y [11]. This implied that CA125 in peritoneal effluent
can possibly be used to study the reported changes in mesothelial
cells of peritoneal dialysis patients. In a previous cross-sectional
study, no relation between CA125 in the effluent of CAPD
patients and peritoneal permeability characteristics could be
found [14]. A negative relation was present with the duration of
CAPD treatment [14]. This suggests a possible loss of mesothelial
cells during CAPD treatment in individual patients. At present,
no data are available on the follow-up of the mesothelium in vivo
by CA 125 concentrations in peritoneal effluent. Also, the extent to
which CA125 can be used as a marker of mesothelial integrity, as
well as the inter- and intraindividual variabilities have not been
established.
In the present study, we attempted to answer these questions by
a longitudinal study in which CA125 was followed over three to
seven years in a large group of patients. The influence of different
intercurrent complications of PD on the mesothelium in these
patients was studied. Furthermore, analysis of the appearance of
CA125 in peritoneal effluent during four hour dwells, as well as
day-to-day variability of CA125 in standardized dwells was per-
formed.
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Patients were included who had been treated with peritoneal
dialysis for at least one year, except for the longitudinal study. All.
patients were free of peritonitis at the time of and during the
month prior to the studies.
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Appearance of CA125 in peritoneal effluent
CAl 25 was measured in effluent during standardized four-hour
dwells at 0, 10, 20, 30, 60, 120, 180 and 240 minutes. Dwells with
3.86% glucose (Dianeal; Baxter NL, Utrecht, the Netherlands)
were compared to 1.36% glucose (Dianeal, Baxter NL) and to
7.5% icodextrin (Icodial; ML Laboratories, St Albans, UK), both
in five patients.
Day-to-day variability
Three stable CAPD patients were studied on a daily basis for six
days. The patients performed standardized four-hour dwells with
1.36% glucose-based dialysate solutions at the beginning of each
day. The exact dwell times and volumes of the bags were recorded.
CA125 was measured in the six bags on consecutive days, and
appearance rates (AR) were calculated by multiplication with the
dwell volume and dividing by the dwell time. Intra-individual
coefficients of variation were calculated as the SD divided by the
mean data from the six days, multiplied by 100. The overall
coefficient of variation was obtained from the overall SD. The
latter was calculated as the square root of the mean of the squares
of the SD data of each patient.
Longitudinal follow-up of CA 125
In 31 patients CA125 was determined in four-hour dwells with
1.36% glucose on a yearly basis during the standard peritoneal
permeability analyses [151. The minimum number of determina-
tions was 3 (11 patients). The interval between the subsequent
determinations had to be at least one year apart. Ten patients
were studied four times, in four patients five investigations were
performed, and six investigations were made in four patients.
Maximum follow-up was seven years (2 patients). This resulted in
a total of 131 studies. The observation period did not necessarily
include the first year of treatment. The mean cross-sectional age
was 49 years, range 21 to 78 years, and the mean peritonitis
incidence 0.30 (0 to 4.5) episodes/year. Duration of peritoneal
dialysis ranged from 0.4 to 10.5 years.
Assays
CA125 was determined using a micropartiele enzyme immuno-
assay, in combination with a commercially available monoelonal
antibody 0C125 (Cis Bio International, France) on an IMx
autoanalyzer (Abbott Laboratories, North Chicago, IL, USA).
Measuring range was 1.8 to 800 U/nil, with normal serum values <
35 U/ml. Interassay variability was 2.3%. The method was vali-
dated for determinations in peritoneal effluents in our laboratory
[101. Samples of one patient were always measured within the
same run, to avoid interassay variability.
Statistical analysis
Data are expressed as mean SEM for data with a normal
distribution, and medians and ranges are given for asymmetrically
distributed data. Linear regression analysis was performed for
individual patients using the method of least squares. Analysis of
trend was performed according to Yellin [16]. For correlations,
Spearman rank correlation analysis was used and the Wilcoxon's
rank-sum test was applied for comparisons of two samples [17].
Results
Appearance of CA 125 in peritoneal effluent
CA125 appearance in the effluent was linear in time during
dwells with 1.36% and 3.86% glucose based dialysate and with
icodextrin (mean regression coefficient 0.97, range 0.93 to 0.99 for
all). The comparison of 3.86% glucose dwells with either 1.36%
glucose (Fig. 1A) or icodextrin (Fig. IB) revealed no difference in
CA125 concentrations at any time point (P> 0.30).
Day-to-day variability
The median CA12S appearance rates were: patient 1, 179
U/mm, range 165 to 198; and patient 2, 155 U/mm, range 131 to
173. Patient 3 showed median values 148 U/mm (range 129 to
167). The mean day-to-day coefficient of variation was 6.4% (5.5
to 8.1) for CA125 appearance rates. The overall coefficient of
variation for CAl 25 appearance rate was 7.7%.
Longitudinal fbllow up
Median cross sectional CA125 concentration was 13.8 U/mI,
range 1.1 to 96.5. A125 appearance rate was 108 U/mm, range 10
to 610. The second year of treatment was assumed to represent
the stable CAPI) situation. In 26 patients observations had been
made within this year of treatment. Mean values were 22.1 2.1
U/mI/four hours for CA125 concentrations and 170 15 U/mm
for the appearance rate. Both CA125 concentrations (r =
—0.51,
P < 0.0001) and appearance rates (r =
—0.49, P < 0.0001) were
inversely related to the duration of CAPD treatment (Fig. 2 for
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Fig. 1. Linear CA 125 release in the effluent
during four-hour dwells in five stable CAPD
patients. In A, 3.86% glucose (•) is compared
to 1.36% glucose (A), and in B, 3.86% glucose
is compared to icodextrin (V). Data are
expressed as mean SEM.
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AR), and very weakly to peritonitis incidence (r = —0.21,P = 0.02
for AR).
After analysis of the trend, based on individual regression
coefficients, a significant negative trend in time was found, with a
mean regression coefficient of —3.80 2.38, P < 0.01, which is
shown in Figure 3. Using this trend, a median decrease of 2.2%
(1.1 to 24.8) per year could be calculated. None of the patients
showed a significant increase of CA125 (regression coefficient >
—3.80 + 1 SEM). The appearance rate of CA125 remained stable
(regression coefficient —3.80 1 SEM) over the years in 11
patients, 4 of whom had values below the 10th percentile of the
whole group thoughout their PD treatment (example given in Fig.
4A). In 20 other patients a significant decrease of the appearance
rate of CA125 was found, which was defined as a regression
coefficient lower than —3.80 to 1 SEM.
Sudden decreases were defined as values < 50% of the
expected value according to the individual regression line of a
patient. Five patients met these criteria, with a range of decrease
of 50 to 97%. An example of a patient from this group in shown
in Figure 4B. The clinical records of these patients were searched
for possible etiological moments. The sudden decrease was pre-
ceded by treatment resistant peritonitis with S. epidermidis in one
patient, and Pseudomonas aeruginosa peritonitis in a second
patient, in whom the diagnosis peritoneal sclerosis was made
shortly afterwards. Multiple peritonitis episodes (5) within one
year occurred in the third patient. A temporary cessation of
peritoneal dialysis preceded the change in CAl 25 in the last two
patients, in one because of a fasela defect (2 months). In the
second patient the reason was a chronic exit site infection (S.
aureus) that required catheter replacement and temporary cessa-
tion of peritoneal dialysis for two weeks. No peritonitis episodes
occurred shortly prior to the decrease in CA12S in these last two
patients.
Discussion
The linear appearance of CA125 in peritoneal effluent of stable
CAPD patients and its small coefficient of intra-individual varia-
tion, as found in the present study, support its use as a marker of
peritoneal mesothelial cell mass or stable mesothelial cell turn-
over. These findings extend previous data based on the relation of
dialysate CA125 with the mesothelial cell count [10], and on in
vitro studies with cultured mesothelial cells [11].
In the present longitudinal study, a negative trend for the
dialysate CA125 appearance rate with time on dialysis treatment
was found. This provides evidence for loss of mesothelial cell mass
during long duration peritoneal dialysis. Such a phenomenon is
supported by scattered morphological studies, both under stable
conditions [1], during peritonitis [2—4] and in the infrequent
complication of peritoneal sclerosis [7]. In theory, loss of me-
sothelial cells could lead to an increased susceptibility to perito-
nitis or to impaired inflammatory control, because the mesothelial
cells are important providers of inflammatory mediators. How-
ever, CAl 25 was only very weakly related to peritonitis incidence
in the present study, and we are not aware of any reports on
increased peritonitis incidence or severity in long-term CAPD
patients. Although late peritonitis [181 and bouts of repeated
episodes of peritonitis [19] may have some influence on mem-
brane permeability, no data on mesothelial integrity were avail-
able in these studies. An alternative explanation for the negative
trend of CA125 with duration of peritoneal dialysis could he that
stabilization of the mesothelial cell population might result in a
decline in CA125 appearance rates. Under those circumstances, a
constant number of mesothelial cells would release a lower
amount of CA125 into the pcritoneal effluent after long-term
peritoneal dialysis. In our opinion, this is not the most plausible
explanation, because rather than stabilization, activation of me-
sothelial cells is induced by peritoneal dialysis [1]. It has further
been shown that activation of a continous monolayer of cultured
mesothelial cells with known stimuli does not lead to an increase
of CAl 25 release [11]. Therefore, it is not very likely that even if
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Fig. 2. CA 125 appearance rates were inversely related to duration of PD
treatment (r =
—0.49, P < 0.001).
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Fig. 3. Analysis of trend, based on the individual regression coefficients, of
CA]25 versus duration of PD treatment (mean regression coefficient —3.80,
SCM 2.38, P < 0.01).
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stabilization of previously stimulated mesothelial cells would
occur, this would affect CA125 appearance rates in the effluent.
Serial determinations of dialysate CA125 allow longitudinal
follow-up of mesothelial cell mass in individual patients, which is
impossible in morphological studies. Our data suggest a gradual
loss of mesothelial cells in most patients on peritoneal dialysis.
However, substantial interindividual differences existed in both
CA125 appearance rates and the velocity of the decrease in
CA125 with the duration of peritoneal dialysis treatment. There-
fore, it seems appropriate to obtain normal values for each patient
and to compare subsequent values to the individual regression
line of a patient. In the follow-up of patients, changes in CA125
concentrations exceeding 10% from day-to-day can be considered
as mesothelial alterations. These data were obtained by the
Abbott IMx CA125 assay, which was validated for measurements
in peritoneal effluents in our laboratory [101. The IMx assay gives
highly reproducible results, and stability proved to be good after
three years at —20CC and in repeated thawing and freezing cycles
(coefficients of variation 7 to 10%). Measurements in serum using
this method have shown better reproducibility when compared to
the Abbott RIA for CA125, as well as better results after sample
dilution [20, 211. The very low detection limit of the assay also is
an advantage for the determination of CA125 concentrations in
dialysis solutions. Data on comparisons of determinations of
CA125 in serum by different assays point to distinct differences in
results, and therefore it is advisable to always use the same
method for follow-up of patients.
Sudden diversions from the regression line of CA125 in an
individual patient should be considered an alarming sign for
mesothelial damage. Tndividual susceptibility and interfering
events seem to influence this process of loss of mesothelial cell
mass. Possible events causing an acute decrease of mesothelial cell
mass found in the present study were severe peritonitis episodes
and temporary cessation of peritoneal dialysis. However, as shown
in a previous study [22], uncomplicated peritonitis does not lead
to changes in dialysate CA125 after recovery. This was supported
the very weak relation between peritonitis incidence and CA125
appearance rates in the present study. It is, however, possible that
distinct microorganisms, such as Pseudomonas species [23] or S.
aureus [24, 25] are either more harmful to the mesothelium, or do
cause more damage to an already injured peritoneum.
In four of our patients CA125 values below the 10th percentile
of the group were found thoughout treatment. Two possibilities
exist for this finding. Firstly, these patients may have a low number
of mesothelial cells from the start, or alternatively, they may have
continous low expression of CA125 in their mesothelial cells. This
last possibility seems to be the most likely, because the percentage
of mesothelial cells that express A1 25 can vary between patients,
but is constant in time in cultured mesothelial cells [11]. In
addition, these four patients did not have a higher peritonitis
incidence than the others, which would have pointed to the
possibility of a lower number of mesothelial cells.
In the extreme situation of peritoneal fibrosis, the absence of
mesothelial cells has been described [7]. The sudden development
of extremely low CA125 concentrations in the only patient who
developed peritoneal sclerosis in this series, indicates a massive
loss of mesothelial cells, probably provoked by the severe perito-
nitis epidsode with Pseudomonas aeruginosa that may have acce].-
erated the process of fibrosis. It suggests that these sudden
decreases in CA125 should be considered as an alarming sign for
the manifestation of peritoneal sclerosis. This contension is
supported by extremely low CA125 concentrations in the effluent
of six patients with peritoneal sclerosis that were found in a
retrospective study [26]. The observation that cessation of perito-
neal dialysis seemed to induce loss of mesothelial cells in two
patients is rather confusing, because "peritoneal rest" has been
proposed as a method of treatment of peritoneal membrane
failure in the past [27, 28]. However, no effects of this treatment
on mesothelial cell mass has been reported in these studies.
The actual cause of the loss of mesothelial cell mass that occurs
remains speculative, but the unphysiological composition of dia-
lyisis solutions may be involved. Adverse effects of peritoneal
dialysis solutions on cultured mesothelial cells have been de-
scribed extensively [reviewed in 8]. Lysis of mesothelial cells can
be caused by high glucose concentrations, high osmolality, and
low pH in combination with lactate in vitro. The extent to which
these data can be extrapolated to the in vivo situation remains
uncertain. It should be appreciated that pH is almost immediately
normalized by the residual volume in the peritoneal cavity [29].
Therefore, in the in vivo setting, high glucose and hyperosmolality
are probably more important. If acute lysis of mesothelial cells
would occur in vivo, this is likely to happen during the initial phase
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differences in CA125 follow-up between patients.
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of a dwell. In theory, this could be reflected in a marked release
of CAl 25 during this phase. However, no such release of CA125
was found, indicating that the unphysiological composition of the
dialysate does not cause lysis of mesothelial cells to such extent
that it influences CA125 concentrations. It implies that the
contribution of acute mesothelial cell loss to four-hour dwell
concentrations of CA125 is negligible.
The detrimental effects of high glucose concentrations on
cultured mesothelial cells could not be confirmed in the present in
vivo study. No effect of dialysate glucose concentration on CA125
appearance rates was found at any time point during the four hour
dwells. Similarly, no effect of hyperosmolality on acute mesothe-
hal cell damage could be established, because CA125 release was
similar during glucose 3.86% (osmolality 486 mOsm/kg H20) and
7.5% icodextrin (282 mOsm/kg H20). It can not, however, be
excluded based on the results of the present study, that chronic
exposure to unphysiological dialysis solutions causes changes in
the peritoneal membrane. Glucose may especially be harmful,
since the continuous exposition to unphysiologically high concen-
trations can lead to non-enzymatic glycosylation [30]. Such effects
are also suggested by a recent finding that glucose exposition may
be an additional risk factor for peritoneal sclerosis in peritoneal
dialysis patients [31]. The effect of chronic exposure of the
mesothelial cells to high glucose concentrations still has to be
determined, and can only be answered when randomized long-
term studies with different osmotic agents will become possible.
It can be concluded that dialysate CA125 is a useful marker for
the follow-up of mesothehial cell mass or stable mesothelial cell
turnover in individual peritoneal dialysis patients. A gradual loss
of mesothelial cell mass occurs in most patients on peritoneal
dialysis. Interindividual differences exist in the velocity of this
process. Events causing a sudden loss of mesothelial cells include
severe peritonitis episodes and possibly temporary cessation of
peritoneal dialysis. A sudden decrease in CA125 must be consid-
ered as an alarming sign for the manifestation of peritoneal
sclerosis. Prospective analysis of CA125 in PD effluent will be
needed to determine the relevance of CA125 as a diagnostic tool
for peritoneal sclerosis.
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